Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model

Molecular Brain

Volumn 7, Issue 1, 2014, Pages

  Li, Wei ^a   Yu, Jia ^b   Liu, Yong ^c   Huang, Xiaojie ^a   Abumaria, Nashat ^a   Zhu, Ying ^a   Huang, Xian ^a   Xiong, Wenxiang ^a   Ren, Chi ^a   Liu, Xian Guo ^c   Chui, Dehua ^b   Liu, Guosong ^a  

^a Tsinghua University   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Alzheimer's disease; BACE1; Brain magnesium; NMDAR signaling; Synaptoprotection

Indexed keywords

BETA SECRETASE 1; CALCINEURIN; MAGNESIUM DERIVATIVE; MAGNESIUM THREONATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, MOUSE; BUTYRIC ACID DERIVATIVE; SECRETASE; THREONIC ACID;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN REGULATION; DRUG BRAIN LEVEL; MALE; MORRIS WATER MAZE TEST; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE; AGING; ANALYSIS OF VARIANCE; ANIMAL; BODY WEIGHT; BRAIN; COGNITION DISORDERS; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FEMALE; HIPPOCAMPUS; HUMAN; LEARNING; MEMORY DISORDERS; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; PLAQUE, AMYLOID; ULTRASTRUCTURE;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANALYSIS OF VARIANCE; ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; BODY WEIGHT; BRAIN; BUTYRATES; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HIPPOCAMPUS; HUMANS; LEARNING; MALE; MEMORY DISORDERS; MICE, TRANSGENIC; MOTOR ACTIVITY; PLAQUE, AMYLOID; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84908222000     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/s13041-014-0065-y     Document Type: Article

References (50)

1. Holtzman DM, Morris JC, Goate AM: Alzheimer's disease: the challenge of the second century. Sci Transl Med 2011, 3:77sr71.
2. Selkoe DJ: Alzheimer's disease. Cold Spring Harb Perspect Biol 2011, 3(7):a004457.
3. Tamayev R, Matsuda S, Arancio O, D'Adamio L: beta- but not gamma-secretase proteolysis of APP causes synaptic and memory deficits in a mouse model of dementia. EMBO Mol Med 2012, 4:171-179.
4. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M: APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
5. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
6. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R: Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991, 30:572-580.
7. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C: Age, neuropathology, and dementia. N Engl J Med 2009, 360:2302-2309.
8. Roe CM, Mintun MA, D'Angelo G, Xiong C, Grant EA, Morris JC: Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol 2008, 65:1467-1471.
9. Sperling RA, Jack CR Jr, Aisen PS: Testing the right target and right drug at the right stage. Sci Transl Med 2011, 3:111cm133.
10. Palop JJ, Mucke L: Amyloid-[beta]-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci 2010, 13:812-818.
11. Greer PL, Greenberg ME: From synapse to nucleus: calcium-dependent gene transcription in the control of synapse development and function. Neuron 2008, 59:846-860.
12. Rockenstein E, Adame A, Mante M, Moessler H, Windisch M, Masliah E: The neuroprotective effects of Cerebrolysin in a transgenic model of Alzheimer's disease are associated with improved behavioral performance. J Neural Transm 2003, 110:1313-1327.
13. Matsuoka Y, Jouroukhin Y, Gray AJ, Ma L, Hirata-Fukae C, Li HF, Feng L, Lecanu L, Walker BR, Planel E, Arancio O, Gozes I, Aisen PS: A neuronal microtubule interacting agent, NAP, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease. J Pharmacol Exp Ther 2008, 325(1):146-153.
14. De Rosa R, Garcia AA, Braschi C, Capsoni S, Maffei L, Berardi N, Cattaneo A: Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A 2005, 102:3811-3816.
15. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH: Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med 2009, 15:331-337.
16. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S: Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008, 70:440-448.
17. 2+ flux during uncorrelated activity. Neuron 2004, 44:835-849.
18. Slutsky I, Abumaria N, Wu LJ, Huang C, Zhang L, Li B, Zhao X, Govindarajan A, Zhao MG, Zhuo M, Tonegawa S, Liu G: Enhancement of learning and memory by elevating brain magnesium. Neuron 2010, 65:165-177.
19. Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 2002, 298:789-791.
20. Andrasi E, Pali N, Molnar Z, Kosel S: Brain aluminum, magnesium and phosphorus contents of control and Alzheimer-diseased patients. J Alzheimers Dis 2005, 7:273-284.
21. Barbagallo M, Belvedere M, Di Bella G, Dominguez LJ: Altered ionized magnesium levels in mild-to-moderate Alzheimer's disease. Magnes Res 2011, 24:S115-S121.
22. Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS: Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939-945.
23. Bernardo A, Harrison FE, McCord M, Zhao J, Bruchey A, Davies SS, Jackson Roberts L 2nd, Mathews PM, Matsuoka Y, Ariga T, Yu RK, Thompson R, McDonald MP: Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Neurobiol Aging 2009, 30:1777-1791.
24. Ding Y, Qiao A, Wang Z, Goodwin JS, Lee ES, Block ML, Allsbrook M, McDonald MP, Fan GH: Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer's disease transgenic mouse model. J Neurosci 2008, 28:11622-11634.
25. Reiserer RS, Harrison FE, Syverud DC, McDonald MP: Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav 2007, 6:54-65.
26. Reagan-Shaw S, Nihal M, Ahmad N: Dose translation from animal to human studies revisited. Faseb J 2008, 22:659-661.
27. Martin SJ, Grimwood PD, Morris RG: Synaptic plasticity and memory: an evaluation of the hypothesis. Annu Rev Neurosci 2000, 23:649-711.
28. Snyder EM, Nong Y, Almeida CG, Paul S, Moran T, Choi EY, Nairn AC, Salter MW, Lombroso PJ, Gouras GK, Greengard P: Regulation of NMDA receptor trafficking by amyloid-[beta]. Nat Neurosci 2005, 8:1051-1058.
29. Cisse M, Halabisky B, Harris J, Devidze N, Dubal DB, Sun B, Orr A, Lotz G, Kim DH, Hamto P, Ho K, Yu GQ, Mucke L: Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 2011, 469:47-52.
30. Bezprozvanny I, Mattson MP: Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 2008, 31:454-463.
31. Jang H, Arce FT, Ramachandran S, Capone R, Azimova R, Kagan BL, Nussinov R, Lal R: Truncated {beta}-amyloid peptide channels provide an alternative mechanism for Alzheimer's Disease and Down syndrome. Proc Natl Acad Sci U S A 2010, 107(14):6538-6543.
32. 2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010, 47:264-272.
33. Kuchibhotla KV, Goldman ST, Lattarulo CR, Wu HY, Hyman BT, Bacskai BJ: Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron 2008, 59:214-225.
34. Shi J, Townsend M, Constantine-Paton M: Activity-dependent induction of tonic calcineurin activity mediates a rapid developmental downregulation of NMDA receptor currents. Neuron 2000, 28:103-114.
35. Lau CG, Zukin RS: NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci 2007, 8:413-426.
36. Dineley KT, Hogan D, Zhang WR, Taglialatela G: Acute inhibition of calcineurin restores associative learning and memory in Tg2576 APP transgenic mice. Neurobiol Learn Mem 2007, 88:217-224.
37. McConlogue L, Buttini M, Anderson JP, Brigham EF, Chen KS, Freedman SB, Games D, Johnson-Wood K, Lee M, Zeller M, Liu W, Motter R, Sinha S: Partial reduction of BACE1 has dramatic effects on Alzheimer plaque and synaptic pathology in APP Transgenic Mice. J Biol Chem 2007, 282:26326-26334.
38. Singer O, Marr RA, Rockenstein E, Crews L, Coufal NG, Gage FH, Verma IM, Masliah E: Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model. Nat Neurosci 2005, 8:1343-1349.
39. Palop JJ, Mucke L: Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol 2009, 66:435-440.
40. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, Finkbeiner S, Noebels JL, Mucke L: Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
41. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR, Devidze N, Ho K, Yu GQ, Palop JJ, Mucke L: Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci U S A 2012, 109:E2895-E2903.
42. Altman D, Carroli G, Duley L, Farrell B, Moodley J, Neilson J, Smith D: Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002, 359:1877-1890.
43. Lu JF, Nightingale CH: Magnesium sulfate in eclampsia and pre-eclampsia: pharmacokinetic principles. Clin Pharmacokinet 2000, 38:305-314.
44. Hubbard JI, Jones SF, Landau EM: On the mechanism by which calcium and magnesium affect the spontaneous release of transmitter from mammalian motor nerve terminals. J Physiol 1968, 194:355-380.
45. Hubbard JI, Jones SF, Landau EM: On the mechanism by which calcium and magnesium affect the release of transmitter by nerve impulses. J Physiol 1968, 196:75-86.
46. Witkowski M, Hubert J, Mazur A: Methods of assessment of magnesium status in humans: a systematic review. Magnes Res 2011, 24:163-180.
47. Morris RG, Garrud P, Rawlins JN, O'Keefe J: Place navigation impaired in rats with hippocampal lesions. Nature 1982, 297:681-683.
48. Ennaceur A, Delacour J: A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 1988, 31:47-59.
49. Leung LW: Orthodromic activation of hippocampal CA1 region of the rat. Brain Res 1979, 176:49-63.
50. Wei F, Qiu CS, Kim SJ, Muglia L, Maas JW, Pineda VV, Xu HM, Chen ZF, Storm DR, Muglia LJ, Zhuo M: Genetic elimination of behavioral sensitization in mice lacking calmodulin-stimulated adenylyl cyclases. Neuron 2002, 36:713-726.